Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1582708 | 0.98 | MAPT (0.33) | ALDH1A1SMN1; SMN2CYP2A13HPGDMAPT | |
| SCHEMBL170248 | 0.94 | SMN1; SMN2 (0.33) | ALDH1A1SMN1; SMN2CYP2A13HPGD | |
| SCHEMBL1428236 | 0.82 | — | — | |
| SCHEMBL157427 | 0.82 | CYP2D6 (0.33) | — | |
| SCHEMBL2229452 | 0.80 | CYP2D6 (0.32) | — | |
| SCHEMBL10891279 | 0.80 | CYP2D6 (0.32) | — | |
| SCHEMBL3658217 | 0.80 | CYP2D6 (0.32) | — | |
| SCHEMBL286072 | 0.80 | CYP2D6 (0.32) | — | |
| SCHEMBL6050828 | 0.80 | CYP2D6 (0.32) | — | |
| SCHEMBL4712511 | 0.80 | CYP2D6 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 278 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210253575-A1 | PYRROLIDINE AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2021-08-19 | — | — | US | claimed |
| EP-3847165-A1 | NOVEL PYRROLIDINE AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2021-07-14 | — | — | EP | claimed |
| CN-112673003-A | Novel pyrrolidine amine compounds for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2021-04-16 | — | — | CN | claimed |
| US-9834513-B2 | Benzylamine derivatives | Kalvista Pharmceuticals Limited (GB) | 2017-12-05 | — | — | US | claimed |
| US-20170253561-A1 | Benzylamine Derivatives | KALVISTA PHARMACEUTICALS LTD (GB) | 2017-09-07 | — | — | US | claimed |
| US-9670157-B2 | Benzylamine derivatives | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2017-06-06 | — | — | US | claimed |
| EP-2364298-B1 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMA CO LTD (JP) | 2016-08-03 | — | — | EP | claimed |
| US-9370519-B2 | Macrocyclic FLT3 kinase inhibitors | ONCODESIGN S.A. (FR) | 2016-06-21 | — | — | US | claimed |
| EP-2760867-B1 | MACROCYCLIC FLT3 KINASE INHIBITORS | ONCODESIGN SA (FR) | 2016-03-16 | — | — | EP | claimed |
| US-20160039752-A1 | BENZYLAMINE DERIVATIVES | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2016-02-11 | — | — | US | claimed |
| EP-0547168-A1 | CERTAIN CYCLOALKYL IMIDAZOPYRIMIDINES, A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1993-06-23 | — | — | EP | claimed |
| EP-0538314-A1 | INDANO PYRROLIDINE CARBAMATES. | PFIZER (US) | 1993-04-28 | — | — | EP | claimed |
| WO-1992004351-A1 | CERTAIN CYCLOALKYL IMIDAZOPYRIMIDINES, A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1992-03-19 | — | — | WO | claimed |
| WO-1992000961-A1 | INDANO PYRROLIDINE CARBAMATES | PFIZER INC. (US) | 1992-01-23 | — | — | WO | claimed |
| EP-0342682-A2 | Hydroxamate derivatives of selected nonsteroidal anti-inflammatory acyl residues having cyclooxygenase and 5-lipoxygenase inhibition | WARNER-LAMBERT COMPANY (US) | 1989-11-23 | — | — | EP | claimed |
| US-4839358-A | ANALGESICS, ANTIDEPRESSANTS, ANTIANXIETY AGENTS | ROUSSEL UCLAF (FR) | 1989-06-13 | — | — | US | claimed |
| US-4816571-A | Chemical capping by phosphitylation during oligonucleotide synthesis | APPLIED BIOSYSTEMS, INC. (US) | 1989-03-28 | — | — | US | claimed |
| EP-0251937-A1 | Tricyclic agonist derivatives of cholinergic receptors, and medicines containing them | SANOFI (FR) | 1988-01-07 | — | — | EP | claimed |
| EP-0031266-B1 | 1-AMINO-2-PROPANOL DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR THERAPEUTIC USE | ELF SANOFI (FR) | 1983-02-09 | — | — | EP | claimed |
| US-4145541-A | ANTIINFLAMMATORY | E. R. SQUIBB & SONS, INC. (US) | 1979-03-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253575-A1 | PYRROLIDINE AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | ARG1, PRMT1, PADI1 | ALDH1A1 942/4885SMN1; SMN2 2019/4885CYP2A13 3887/4885 |
| US-20160039752-A1 | BENZYLAMINE DERIVATIVES | BDKRB1, BDKRB2, KLKB1 | ALDH1A1 2364/4885SMN1; SMN2 2831/4885CYP2A13 1586/4885 |
| US-20170253561-A1 | Benzylamine Derivatives | BDKRB1, BDKRB2, KLKB1 | ALDH1A1 2364/4885SMN1; SMN2 2831/4885CYP2A13 1586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.